Dr Lalchandani Labs Ltd. Share Price

Pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (‘SEBI Listing Regulations’) Fortis Malar Hospitals has informed that the Board of Directors of the Company at its meeting held today, Monday, May 18, 2026, considered and approved the following: - 1. Financial Results: Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026 along with Statement of Assets and Liabilities as on March 31, 2026. B S R & Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with an unmodified opinion on the Standalone and Consolidated Financial Statements. Accordingly, the standalone and consolidated audited financial results, auditors’ reports, Statement of Assets & Liabilities, and declaration pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, regarding Unmodified Opinion on the Audited financial results for the financial year ended March 31, 2026 are enclosed; 2. Adoption of Policies: a. The modification in the policy for the determination of Materiality of Events/Information, which also contains the details of persons authorized to determine the Materiality of the Event/Information for the purpose of disclosures to Stock Exchange. The said revised policy has been enclosed. b. The updated Policy/Code of Conduct for the prevention of Insider Trading. The said updated policy/Code has also been enclosed. The Board Meeting commenced at 11:30 am (IST) and concluded at 03:35 pm (IST). The same is also uploaded on the website of the Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 29 of the Securities and Exchange Board of India (LODR) Regulations, 2015, MPS Pharmaa has informed that as per the requirements of Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations, 2015, a meeting of the Board of Directors of the company is scheduled to be held on Thursday, 28th May, 2026 at 12:00 pm at the corporate office of the company at 703, Arunachal Building, 19, Barakhambha Road, Connaught Place, New Delhi-110001, to transact the following business: 1. To consider and approve the Audited Financial Results of the Company for the quarter and Financial Year ended 31st March, 2026. 2. To consider and approve the Auditors’ Report on the Audited Financial Results of the Company for the quarter and Financial Year ended 31st March, 2026. 3. To consider the appointment of Sanghi & Co., Chartered Accountants as the Internal Auditor of the Company for the F.Y. 2026-27. 4. To carry on any other business with the permission of the Board. Further, pursuant to BSE Circular no. LIST/COMP/01/2019-20 dated April 02, 2019 and in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulation, 2015, the trading window for dealing in the shares of the Company for all Directors/Officers/Designated Employees of the Company and their relatives, is already closed for the purpose of declaration of Audited Financial Results for the quarter and Financial Year ended 31st March, 2026. Accordingly, the trading window of the company shall remain closed till 30th May, 2026.